Publications

5674 Results

SWOG S0820/PACES (Preventing Adenomas of the Colon with Eflornithine and Sulindac), A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial - NCT01349881

Authors
J Zell;J Unger;G Anderson;E Cook;J Krouse;P Lance;L Minasian;L Ford;P Brown
Journal / Conference
Journal of Clinical Oncology 33:5s (suppl; abstr TPS3627); American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), poster session;
Year
2015
Research Committee(s)
Prevention, Screening, and and Surveillance
Study Number(s)
S0820

SWOG S1320: A randomized phase II trial of intermittent versus continuous dosing of dabrafenib and trametinib in BRAFV600E/K mutant melanoma

Authors
A Algazi;M Othus;A Daud;J Mehnert;C Lao;R Kudchadkar;K Grossmann;R Lo;J Moon;J Kirkwood;A Ribas
Journal / Conference
Journal of Clinical Oncology 33:5s (suppl; abstr TPS9093); American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), poster session;
Year
2015
Research Committee(s)
Melanoma
Study Number(s)
S1320

SWOG S1404: A phase III randomized trial comparing high dose interferon to MK-3475 (pembrolizumab) in patients with high risk resected melanoma

Authors
K Grossmann;M Othus;A Tarhini;S Patel;J Moon;V Sondak;J Kirkwood;A Ribas
Journal / Conference
Journal of Clinical Oncology 33:5s (suppl; abstr TPS9085); American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), poster session;
Year
2015
Research Committee(s)
Melanoma
Study Number(s)
S1404

SWOG S9005: double blind phase III randomized trial of the anti-progestin agent mifepristone in the treatment of unresectable meningioma

Authors
H Ji;C Rankin;S Grungerg;J Ahmadi;L Feun;R Fredericks;C Russell;F Kabbinavar;K Stelzer;A Schott;C Verschraegen
Journal / Conference
Journal of Clinical Oncology 33:5s (suppl; abstr e17084); American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), publication only;
Year
2015
Research Committee(s)
Brain
Study Number(s)
SWOG-9005

Long term consequences of intermittent and continuous androgen deprivation in patients with metastatic prostate cancer

Authors
D Hershman;JM Unger;J Wright;S Ramsey;C Till;C Tangen;W Barlow;C Blanke;IM Thompson;M Hussain
Journal / Conference
Journal of Clinical Oncology 33:5s (suppl; abstr 5008); American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), oral presentation;
Year
2015
Research Committee(s)
Genitourinary
Study Number(s)
SWOG-9346

Creating a national collaborative strategy to enhance trial accrual in NCI’s National Clinical Trials Network (NCTN) in the era of precision medicine

Authors
A Denicoff;G Schroer;H Massett;R Bangs;J Berlin;M Bischoff;F Desanto;A Duli;S Hartson-Stine;E Horvath;R Lambersky;M Katz;S Ramalingam;W Williams;N Seibel;W McCaskill-Stevens;M Mooney;J Abrams
Journal / Conference
Journal of Clinical Oncology 33:5s (suppl; abstr LBA500); American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), poster session;
Year
2015
Research Committee(s)
Cancer Care Delivery

Relationship between metformin use and recurrence and survival in patients (pts) with resected stage III colon cancer (CC) Receiving Adjuvant Chemotherapy: Results from NCCTG N0147 (Alliance).

Authors
PP Singh;Q Shi;N Foster;A Grothey;A Shields;FA Sinicrope;DJ Sargent;SR Alberts
Journal / Conference
Journal of Clinical Oncology 33:5s (suppl; abstr 3531); American Society of Clinical Oncology Annual Meeting (May 29-June 2,2015, Chicago, IL), poster session;
Year
2015
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/N0147

Cost of chemotherapy for metastatic colorectal cancer with either bevacizumab or cetuximab: economic analysis of CALGB/SWOG 80405

Authors
D Schrag;A Dueck;M Naughton;D Niedzwiecki;C Earle;J Shaw;A Grothey;H Hochster;C Blanke;A Venook
Journal / Conference
Journal of Clinical Oncology 33:5s (suppl; abstr 6504); American Society of Clinical Oncology Annual Meeting (May 29-June 2,2015, Chicago, IL), oral;
Year
2015
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80405

Randomized phase II study of everolimus alone (E) versus everolimus plus bevacizumab (E+B) in patients with locally advanced or metastatic pancreatic neuroendocrine tumors, CALGB 80701

Authors
M Kulke;D Niedzwiecki;N Foster;B Fruth;H Kennecke;E Wolin;A Venook
Journal / Conference
Journal of Clinical Oncology 33:5s (suppl; abstr 4005); American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), oral;
Year
2015
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80701

ALCHEMIST: a clinical trial platform to bring genomic discovery and molecularly targeted therapies to early-stage lung cancer

Authors
DE Gerber;GR Oxnard;SJ Mandrekar;S Dahlberg;S Malik;M Mooney;J Abrams;P Janne;T Li;S Ramalingam;E Vokes;R Govindan
Journal / Conference
Journal of Clinical Oncology 33:5s (suppl; abstr TPS7583); American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), poster session;
Year
2015
Research Committee(s)
Lung
Study Number(s)
CTSU/E4512